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Abstract  
Objectives. To explore the in vitro and in vivo antimalarial potential of caffeic acid and derivatives.  
Methods. Two common phenolic acids (caffeic acid and chlorogenic acid) were evaluated for in 
vitro and in vivo antiplasmodial activities in comparison with some semi-synthetic derivatives that 
were synthesized. An in vitro assay based on plasmodial lactate dehydrogenase activity, and the 
classical in vivo 5-days suppressive test from Peters on an artemisinin-resistant P. berghei strain 
were used. Parasitic stage sensitivity to ethyl caffeate was determined in this work. Key findings. 
Phenolic acid esters derivatives showed better antiplasmodial activity than corresponding phenolic 
acids. The derivative with the highest in vitro activity being caffeic acid ethyl ester, exhibiting an 
IC50 = 21.9 ± 9.4 µM. Ethyl caffeate and methyl caffeate were then evaluated for antimalarial 
activity in vivo and ethyl caffeate showed a growth inhibition of 55% at 100 mg/kg. Finally, it 
seems that ethyl caffeate blocks the growth of young parasitic forms. Conclusions. Our study 
provides evidence for an antimalarial potential of caffeic acid derivatives which are common in 
several medicinal plants traditionally used against malaria. It also demonstrates the possibility to 
use such derivatives in the treatment of malaria. 
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Malaria is a major public health problem worldwide, especially in tropical and subtropical 
countries. The global number of malaria cases and deaths was estimated to have decreased since 
2005 due to the expansion of access to rapid diagnostic tests, quality assured artemisinin 
combination therapy, known as ACT (311 million courses were produced in 2015) and increased 
funding for malaria control programs (US$ 2.9 billions in 2015).[1]  However, malaria is still the 
most deadly parasitic disease in the world, with an estimated 216 million cases in 2016.[1]  For the 
first time since long ago, the number of registered cases has not decreased between 2015 and 2016 
(from 212 to 216 million cases). Children, pregnant women, HIV patients and travelers to sub-
Saharan African countries are particularly at risk of severe malaria, if infected with P. falciparum. 
Malaria remains a major killer of under-fives, claiming the life of 1 child every 2 minutes.[1,2]  
The emergence and rapid spread of antimalarial drug-resistant strains of P. falciparum, of 
insecticides resistant mosquitoes and the absence of effective vaccine (Mosquirix® vaccine 
currently evaluated shows only a protection of about 30%)[3] made it more difficult to fight against 
this scourge. This alarming situation highlights the urgent need to discover new antimalarial 
molecules. Natural phenolic compounds, commonly found in various plants, and some of their 
simple esters are known for several biological activities, such as: anti-inflammatory,[4,5]  
antioxidant,[6]  anti-diabetic,[7] anti-carcinoma,[8] antibacterial,[9] and immunomodulatory.[10] Among 
phenolic metabolites, caffeic acid and derivatives (such as chlorogenic,..) are the most frequently 
found, and could be present in high quantities in some plants used as antimalarial traditional 
medicines, but also in foods (coffee beans, thyme, mint, wine, several fruits and vegetables…).[11,12] 
Caffeic acid or simple derivatives have never been evaluated for antimalarial activity, even if 
present in numerous medicinal plants traditionally used as antimalarials. Having found in our 
previous works on antimalarial traditional plants a moderate antimalarial activity for caffeic acid 
that could explain in part the activity of some traditional medicines (data not published), we wanted, 
in this publication, to confirm this finding and to evaluate the in vitro and particularly in vivo 
activity of some semi-synthesized close derivatives to caffeic acid. For in vivo activity assays, an 
artemisinin-resistant P. berghei strain was developed, to demonstrate the potential of evaluated 
compounds against such resistant strains. This study shows for the first time that caffeic acid ethyl 
ester possess in vitro antiplasmodial activity against P. falciparum and in vivo antimalarial activity 
against P. berghei in mice. 
 
Materials and methods 
 
Chemicals and reagents 
All chemical solvent  and reagent were purchased from LiChrosolv, Merck Germany and HiPerSolv 
Chromanorm, VWR Chemicals EC, abcr, Acros Organics, Alfa Aesar, Fisher Chemical, Janssen 
Chimica, Merck, Sigma-Aldrich. 
 
General experimental procedures 
Melting points were determined on a Stuart SMP3 capillary apparatus and are uncorrected. The 1H 
NMR spectra were taken on a Bruker Advance 500 (500 MHz) instrument equipped with cryoprobe 
in DMSO-d6 with TMS as an internal standard; chemical shifts are reported in δ values (ppm) 
relative to internal TMS. The abbreviation s = singlet, d = doublet, t = triplet, q = quadruplet, quint 
= quintuplet, m = multiplet, and b = broad are used throughout. Elemental analyses (C, H, N, S) 
were realized on a a FlashEA 1112 series (Thermo-Interscience) and were within 0.4% of the 
theoretical values. All reactions were routinely checked by TLC on silica gel Merck 60F254. MS 
detection was carried out using Micromass ESI-Q-TOF II instrument using ESI ionization in the 
positive mode (Waters). The UV spectra were acquired using a U-2910 spectrophotometer. 
 
Fischer esterification (for 2a-g) 
A solution of the suitable carboxylic acid 1-2 (for instance 1, 200 mg, 1.11 mmol) or methyl ester 3 
in the appropriate alcohol (8 ml) was heated under reflux with concentrated sulfuric acid (0.2 ml). 
After 2 hours, the mixture was cooled down and ethyl acetate was added. The resulting organic 
phase was washed by a NaHCO3 aqueous solution (5% w/v), water and then dried over anhydrous 
magnesium sulfate. After filtration of the drying agent, removal of the solvent under vacuo gave the 
pure expected compound. 
 
Methyl caffeate (2a). yield = 95%. mp=155.6-158.9°C (lit. : 158°C) ; 1H NMR (DMSO-d6) d 3.69 
(CH3, s, 3H), 6.27 (Ar-CH=CH, d, J = 15.9 Hz, 1H), 6.76 (5-H, d, J = 8.1Hz, 1H), 7.00 (6-H, d, J = 
8.2 Hz, 1H), 7.03-7.09 (2-H, m, 1H), 7.48 (Ar-CH=CH, d, J=15.9 Hz, 1H), 9.37 (Ar-OH, bs, 2H). 
Anal. (C10H10O4) theoretical: C, 61.85; H, 5.19. Found: C, 61.97; H: 5.32. MS m/z : 193 [M]+, 161, 
134. UVmax : 218, 295 et 324nm. 
 
Ethyl caffeate (2b). yield = 84%. mp=140.8-143.1 °C (lit. 143-146 °C) ; 1H NMR (DMSO-d6) d 
1.24 (CH2CH3, t, J = 7.1 Hz, 3H), 4.15 (CH2CH3, q, J = 7.1 Hz, 2H), 6.25 (Ar-CH=CH, d, J = 15.9 
Hz, 1H), 6.75 (5-H, d, J = 8.2 Hz, 1H), 7.00 (6-H, d, J = 8.1 Hz, 1H), 7.04 (2-H, d, J = 2.1 Hz, 1H), 
7.47 (Ar-CH=CH, d, J=15.9 Hz, 1H), 9.61 (Ar-OH, bs, 2H). Anal. (C11H12O4) theoretical: C, 63.45; 
H, 5.81. Found: C, 63.79; H, 5.91. MS m/z : 208 [M]+, 179, 161 ; UVmax : 218, 295 et 324nm. 
 Isopropyl caffeate (2c). yield = 62%. mp=129.8-135.0 °C (lit. 141-143 °C) ; 1H NMR (DMSO-d6) 
d 1.24 (CH(CH3)2, d, J = 6.3 Hz, 6H), 4.99 (CH(CH3)2, q, J = 6.2 Hz, 1H), 6.22 (Ar-CH=CH, d, J = 
15.9 Hz, 1H), 6.75 (5-H, d, J = 8.1 Hz, 1H), 6.99 (6-H, dd, J = 2.1/8.2 Hz, 1H), 7.03 (2-H, d, J = 2.1 
Hz, 1H), 7.40 (Ar-CH=CH, d, J=15.9 Hz, 1H), 9.35 (Ar-OH, bs, 2H). Anal. (C12H14O4) theoretical: 
C, 64.85; H, 6.35. Found: C, 64.78; H, 6.36. 
 
Ethyl cinnamate (2f). yield = 48%. Oil. 1H NMR (DMSO-d6) d 1.25 (CH2CH3, t, J = 7.1 Hz, 3H), 
4.18 (CH2CH3, q, J = 7.1 Hz, 2H), 6.50 (Ar-CH=CH, d, J = 16.1 Hz, 1H), 7.43 (3-H/4-H/5-H, m, 
3H), 7.67 (Ar-CH=CH, d, J=16.0 Hz, 1H), 7.73 (2-H/6-H, m, 2H). Anal. (C11H12O3) theoretical: C, 
68.74; H, 6.29. Found: C, 68.35; H, 6.33. 
 
Ethyl 3-hydroxycinnamate (2d). yield = 68%. mp=62.9-68.5 °C (lit. 69 °C) ; 1H NMR (DMSO-d6) 
d 1.25 (CH2CH3, t, J = 7.1 Hz, 3H), 4.18 (CH2CH3, q, J = 7.1 Hz, 2H), 6.50 (Ar-CH=CH, d, J = 
16.0 Hz, 1H), 6.83 (6-H, ddd, J = 1.0/2.5/8.0 Hz, 1H), 7.03 (2-H, t, J = 2.0 Hz, 1H), 7.13 (4-H, dt, J 
= 1.2/7.8 Hz, 1H), 7.21 (5-H, t, J = 7.8 Hz, 1H), 7.55 (Ar-CH=CH, d, J=16.0 Hz, 1H), 9.64 (Ar-OH, 
s, 1H). Anal. (C11H12O3) theoretical: C, 68.74; H, 6.29. Found: C, 68.35; H, 6.33. 
 
Ethyl 4-hydroxycinnamate (2e). yield = 67%. mp=70.0-71.0 °C (lit. 73-74 °C) ; 1H NMR 
(DMSO-d6) d 1.24 (CH2CH3, t, J = 7.1 Hz, 3H), 4.16 (CH2CH3, q, J = 7.1 Hz, 2H), 6.39 (Ar-
CH=CH, d, J = 16.0 Hz, 1H), 6.78 (Ar-H, m, 2H), 7.55 (Ar-H/Ar-CH=CH, m, 3H), 10.01 (Ar-OH, s, 
1H). Anal. (C11H12O3) theoretical: C, 68.74; H, 6.29. Found: C, 68.48; H, 6.41. 
 
Ethyl 3',4'-dimethoxycinnamate (2g). yield = 47%. m.p. : 56,1°C (lit. : 56°C). 1H NMR (DMSO-
d6) d 1.25 (CH2CH3, t, J = 7.1 Hz, 3H), 3.80 (OCH3, s, 6H), 4.17 (CH2CH3, q, J = 7.1 Hz, 2H), 6.54 
(Ar-CH=CH, d, J = 15.9 Hz, 1H), 6.99 (5-H, d, J = 8.3 Hz, 1H), 7.23 (6-H, dd, J = 1.9/8.3 Hz, 1H), 
7.36 (2-H, d, J = 1.9 Hz, 1H), 7.58 (Ar-CH=CH, d, J = 15.9 Hz, 1H). Anal. (C13H16O4) theoretical: 
C, 66.09; H, 6.83. Found: C, 66.47; H, 6.96. 
 
Methyl 3',4'-dimethoxycinnamate (3). A mixture of caffeic acid (1a, 500 mg, 2.78 mmol) and 
anhydrous potassium carbonate (1.92 g) in acetone (30 ml) was stirred during 15 minutes at 40°C. 
Dimethylsulfate (2.6 ml, 27 mmol) was added to the medium and the mixture was heated under 
reflux at 70°C during 5 hours. The solid was removed by filtration and washed with acetone. The 
filtrate was evaporated under vacuo. To the residue was added ethyl acetate; the resulting solution 
was washed with water and a NaHCO3 aqueous solution (5% w/v), dried over anhydrous 
magnesium sulfate and evaporated under vacuo. The solid obtained by crystallisation in a cold 
ethanol-water mixture was collected by filtration and characterized as methyl 3',4'-
dimethoxycinnamate (3, 0.34 g, 55%). mp=70.1°C (lit. 68-69 °C). 1H NMR (DMSO-d6) d 3.71 
(COOCH3, s, 3H), 3.81 ((OCH3)2, s, 6H), 6.57 (Ar-CH=CH, d, J = 16.0 Hz, 1H), 6.98 (5-H, d, J = 
8.3 Hz, 1H), 7.23 (6-H, dd, J = 1.9/8.3 Hz, 1H), 7.36 (2-H, d, J = 1.9 Hz, 1H), 7.59 (Ar-CH=CH, d, 
J = 16.0 Hz, 1H). Anal. (C12H14O4) theoretical: C, 64.85; H, 6.35. Found; C, 64.80;H, 6,25. 
 
Fischer esterification (for 5a-b) 
A solution of the chlorogenic acid 4 (0.15 g, 0.42 mmol) in the appropriate alcohol (20 ml) was 
heated under reflux with concentrated sulfuric acid (0.2 ml). After 1 hour at 70°C, the mixture was 
cooled down, water (10 ml) and ethyl acetate (10 ml) were added. The solution was extracted three 
times with AcOEt and the combined organic phases were dried with MgSO4 and concentrated in 
vacuo. 
 
Methyl chlorogenate (5a). 92 mg, yield = 59 %. m.p. : 160°C (dec). 1H NMR (DMSO-d6) d 1.76 
(6’-H, dd, J = 13.1, 7.8 Hz, 1H), 1.91 (2’-H, dd, J = 13.2, 4.0 Hz, 1H), 2.10 (2’-H/6’-H, m, 2H), 
3.58 (4-H, m, 1H), 3.56 (CH3, s, 3H), 3.89 (5’-H, m, 1H), 5.07 (3’-H, td, J = 6.9, 4.0 Hz, 1H), 6.11 
(Ar-CH=CH, d, J = 15.6 Hz, 1H), 6.77 (5-H, d, J = 8.0 Hz, 1H), 6.96 (6-H, dd, J = 2.1/8.2 Hz, 1H), 
7.01 (2-H, d, J  = 2.1 Hz, 1H), 7.39 (Ar-CH=CH,d, J = 15.8 Hz, 1H) 
 
Ethyl chlorogenate (5b). 57 mg, yield = 35%. m.p. : 140°C (dec). 1H NMR (DMSO-d6) d 1.14 
(CH2CH3, t, J = 7.1 Hz,3H), 1.76 (6’-H, dd, J = 13.1, 7.8 Hz, 1H), 1.91 (2’-H, dd, J = 13.2, 4.0 Hz, 
1H), 2.10 (2’-H/6’-H, m, 2H), 3.58 (4-H, m, 1H), 3.75 (CH2CH3, q, J = 7.1 Hz, 2H), 3.89 (5’-H, m, 
1H), 5.07 (3’-H, td, J = 6.9, 4.0 Hz, 1H), 6.11 (Ar-CH=CH, d, J = 15.6 Hz, 1H), 6.77 (5-H, d, J = 
8.0 Hz, 1H), 6.96 (6-H, dd, J = 2.1/8.2 Hz, 1H), 7.01 (2-H, d, J  = 2.1 Hz, 1H), 7.39 (Ar-CH=CH,d, 
J = 15.8 Hz, 1H). 
 
Antiplasmodial activity assay 
Activity against P. falciparum chloroquine-sensitive 3D7 strains was assessed following the 
procedure already described in Frédérich et al.[13] The parasites were obtained from Prof. Grellier 
(Museum d’Histoire Naturelle, Paris, France). Each compound, fraction and extract was applied in a 
series of eight 2-fold dilutions (final concentrations ranging from 0.8 to 100 µg/ml for an extract 
and from 0.08 to 10 µg/ml for a pure substance) on two rows of a 96-well microplate and were 
tested in triplicate (n = 3). Parasite growth was estimated by determination of lactate dehydrogenase 
activity as described previously in Jonville et al.[14] Artemisinin (98%, Sigma-Aldrich) was used as 
positive control.  
    
Selection and cloning of artemisinin resistant parasites 
Plasmodium berghei sensitive to artemisinin, stored in liquid nitrogen, was used. 200 µl of parasite 
suspension were inoculated by caudal intravenous into donor mice. 105 infected red blood cells 
from donor mice were diluted in 0.2ml of 9‰ NaCl  and inoculated by tail intravenous  into 2 
groups of five mice. Immediately, first group received orally an infra therapeutic dose of 
artemisinin freshly prepared in a solvent system (water:DMSO:Tween 80 ; 85:14.7:0.3) consisting 
of 1,25 mg/kg. These mice received artemisinin treatment once a day for 3 days. After seven day, 
parasites which survived this treatment were sub-inoculated into uninfected mice and treatment was 
repeated with 2,5 mg/kg. Subsequently, increasing doses have been scaled each week from 2,5 
mg/kg to achieve finally 30 mg/kg (Figure S1). To discard the possibility that increases in drug 
tolerance were due to increased virulence caused by multiples sub-inoculation, an artemisinin 
sensitive parasite line was maintained in parallel and passaged in untreated mice the same number 
of times as the drug selected line. The evolution of parasitemia of the two lines within 27 weeks of 
subinoculation is shown in Figure S2. 
 
Evaluation of artemisinin resistance 
Resistance quantification in drug-selected parasites clones was established in the following 
way. Using a dose-response curve, ED50 was assessed in drug-selected parasites and untreated 
control lines. A resistance index (RI) was determined using the following equation: RI = DE50 drug-
selected parasites / DE50 artemisinin-sensitive parasite. At the end of the experiment, the ED50 of 
the resistant strain and that of the susceptible strain were determined and the results were as 
following: 36.11 ± 1.39 mg/kg and 6.36 ± 0.54 mg/kg respectively for the isolated resistant strain 
and the starting sensitive strain, so a resistance index of 5.67 compared to initial strain. 
 
In vivo antimalarial assay 
Animal experiments were approved by the ethical committee of the « comité scientifique de 
recherche et de développement de l'Institut Malgache de Recherches Appliquées » under the 
number LEPC-IMRA/2014/07/01, the 18th of July 2014. In vivo antimalarial activity was evaluated 
in the previously developed artemisinin resistant strain of Plasmodium berghei with the method 
described by Peters. [15] Test compounds were dissolved in 20% tween and 80% distilled water, 
different concentration of compound (25, 50 and 100mg/kg) were prepared. Twenty-five mice were 
infected intraperitoneally with 107 infected red blood cells on day 0. Animals were divided into 5 
groups of 5 mice each (vehicle control group, artemisinin group and 3 experimental groups 
receiving respectively: 25, 50 and 100mg/kg). One hour post-infection mice were treated with a 
single dose of test compound by intraperitoneal administration (0,2 ml/mouse/day). Doses of 
various compounds were administered to mice for four days (day 0 to 3). 24 hours after the last 
treatment, blood smears are prepared from tail incision and percent reduction of parasitemia was 
calculated in various groups and ED50 was determined from doses-effect curves.     
   
Identification of in vivo stage sensitivity to ethyl caffeate  
Identification of stage sensitivity for ethyl caffeate was performed on Plasmodium vinckei petteri 
purchased from Prof. Grellier (Muséum National d’Histoire Naturelle, Paris, France). The strain 
was selected for this study because of its high synchronicity.[16] Another advantage when working 
with this strain is the fact that schizogony occurs 24 hours after inoculation and the timing of the 
various parasitic stages can be set up precisely.[17] For convenience, the intraerythrocytic cycle 
which occurs within 24 h was subdivided into five different stages: ring (R), young trophozoite 
(YT), mid-term trophozoite (MT), old trophozoite (OT) and schizont (S). The synchronicity was 
reinforced by rapid freezing and thawing which eliminates all or most parasite stages except the 
merozoites. At the time of inoculation, merozoites of P. vinckei petteri rapidly penetrate the 
erythrocytes.[18] When mice were inoculated at T0, ring appeared at T0+3h, young trophozoites at 
T0+6h, midterm trophozoites at T0+12h and old trophozoites at T0+18h. 
       Parasitic stages were classified using microscope and the following procedures[19]: R, less than 
1/3 of the erythrocyte (RBC) in size, displaying a large vacuole and a tiny ring of cytoplasm; YT, 
about 1/3  of the RBC in size, having a large vacuole and little or no pigment; MT, between 1/3 and 
2/3 of the RBC in size, smaller vacuole than in the previous stage, and containing tine pigment 
particles; OT, 2/3 of the RBC in size, exhibiting small or no vacuole, dense cytoplasm, coarse and 
abundant pigment and S more than 2/3 of RBC in size, no vacuole, dense cytoplasm, abundant 
pigment and exhibiting more merozoites nuclear.   
       Mice were infected intraperitoneally with 107 infected red blood cells. Treatment with ethyl 
caffeate was started 3 days post infection when parasitemia was comprised between 1 % and 8 %. 
Animals were distributed into 6 groups : 5 treated groups and 1 control group. Each treated group 
received the same dose of ethyl caffeate at respectively H0, H0+3, H0+6, H0+12 and  H0+18 (when 
one of 5 stages defined above was highly predominant). They were treated with a single dose of 100 
mg/kg prepared as described for the in vivo antimalarial test. Following treatment, parasitemia and 
parasitic pattern (percentage of each stages) were evaluated at H0, H0+3, H0+6, H0+12, H0+18, 
H0+24 on thin blood smears and compared with those of control mice. Analysis of these parameters 
enabled the identification of the most sensitive stage (or stages) and provided an estimation of the 
duration of drug action. 
Statistical analysis 
In vivo results reflecting inhibition of parasite growth were analyzed using the Kruskal-Wallis test. 
Individual differences between treatments were evaluated using Dunn's test. Analysis was 
performed using Prism 5.0. 
Determination of LogP 





The compounds of interest were prepared from diversely substituted cinnamic acids 1a-d using 
Fischer’s method in the appropriate alcohol with concentrated sulfuric acid. This procedure was 
also followed to carry out a transesterification starting from methyl 3',4'-dimethoxycinnamate 3 to 
obtain the corresponding ethyl ester 2g. Minor modifications of this method were applied in order to 
obtain the chlorogenic derivatives 5a-b (see Figure 1). 
In vitro antiplasmodial activity 
Caffeic and chlorogenic acid and the seven synthetic derivatives were evaluated for their in vitro 
antiplasmodial activity against Plasmodium falciparum. Artemisinin was used as positive control 
and showed an IC50 value of 3.9 ng/ml. All results are presented in Table I.  
In vivo antimalarial activity. 
Methyl and ethyl esters of caffeic acid (2a and 2b), the most active derivatives, were then evaluated 
in vivo against Plasmodium berghei. The experiment was conducted on a P. berghei strain resistant 
to artemisinin. This strain was developed in the LEPC laboratory as explained in experimental part. 
The methyl and ethyl caffeate derivatives showed a dose-dependent antimalarial activity for the 
following doses (25mg/kg, 50mg/kg and 100mg/kg), but only ethyl caffeate at 100 mg/kg showed a 
statistically significant activity with a growth inhibition of about 55%. The inhibitions of parasites 
growth are detailed in Figure 2.  
Determination of stage specificity for ethyl caffeate 
Parasites were able to achieve a full cycle throughout the experiment which allowed us to interpret 
the results. Indeed, in the control group which received only the solvent, overall parasitemia 
increased from 7 to 24% in one cycle. At beginning (H0), predominant parasitic form is the young 
trophozoite. Mid-term trophozoites, old trophozoites and schizonts were respectively found at  
H0+3 (until H0+6), at H0+12 and at H0+18. This kinetic is taken as reference for result 
interpretation.  
Concerning the group treated at H0 with ethyl caffeate, the parasitemia observed at the end of the 
cycle (at H0+24), is 8% inferior to that observed in control group. This difference is not observed 
when treatment is given at H0+3, H0+6 or H0+12. We could then conclude that ethyl caffeate is 
particularly active on young trophozoites as artemether, which makes difference with chloroquine.  
Detailed kinetics are given in Tables S3-S7. 
 
Discussion 
Ethyl and isopropyl, followed by methyl- caffeate presented the best antiplasmodial activity with an 
IC50 around 20 µM against the 3D7 chloroquine sensitive strain of Plasmodium falciparum. This 
range of activity is not extremely potent, but caffeic acid is present in numerous plants used as food 
or medicine and is considered as nontoxic, as probably its simple esters.[11,12] Chlorogenic acid and 
its esters were significantly less active than caffeic acid and its esters, but these compounds could 
be transformed in caffeic acid in the digestive track.  
 
Esterification of the carboxylic acid of 1 is correlated with a four times increase of the in vitro 
activity. Small alkyl esters present similar IC50 values. The importance of the presence of the 2 
phenolic functions was confirmed after the evaluation of compounds 2d-g: for these four 
compounds, a huge reduction of the in vitro activity was observed, compared to the corresponding 
ethyl caffeate (2b). The presence of two phenolic functions appeared then mandatory, and this could 
suggest a link between the antiplasmodial activity and some antioxidant potential, as other phenolic 
compounds with antioxidant activity such as ellagic acid or gallic acid have demonstrated 
antiplasmodial activity.[20,21] In this later case, it is also an ethyl ester of gallic acid which has 
demonstrated better activity.[21] This point has to be investigated in the future. 
 
Many biological activities are attributed to esters derivatives of caffeic acids, such as anti-
inflammatory activity, anti-cancer by induction of apoptosis, antimicrobial, immunomodulatory, as 
described in the introductory part of this manuscript. Furthermore, it has been shown previously that 
caffeic is absorbed in rats, and has an absolute bioavailability in humans around 95%.[22,23] To the 
best of our knowledge, there is no data available about caffeic acid ethyl ester bioavailability, but a 
publication showed that caffeic acid phenetyl ester was resorbed in rats.[24] Caffeic acid and 
derivatives could then explain, at least in part, the oral antimalarial activity of traditional medicinal 
plants where these compounds are abundant. One hypothesis for better activity of ethyl caffeate 
compared to caffeic acid could be the ability to reach intracellular targets which could be related to 
the better lipophilicity of ester derivatives, as illustrated by Log P value in Table 1. Previous works 
found in the literature showed that the esterification of caffeic acid or other phenolics increases their 
lipophilicity thus facilitating their transmembrane passage.[25,26] 
 
In vivo antimalarial activity evaluation was conducted only on the methyl and ethyl caffeic acid 
derivatives which were among the three most active compounds and which were the most easily 
synthesized compounds. In vivo assay confirmed the best activity and dose-dependent effect for 
ethyl caffeate. 
Only ethyl caffeate was studied for chronotherapy because of its better in vivo antimalarial activity. 
Results showed that ethyl caffeate would act preferentially in the 6 first hours of the schizogonic 
cycle by blocking the growth of young parasites (ring and young trophozoites), similarly to what is 
described for artemisinin derivatives.    
 
Conclusions 
Caffeic acid and close derivatives or analogues were shown to exhibit some antiplasmodial activity 
against P. falciparum. Particularly, the ethyl ester of caffeic acid was shown to be the most active 
derivative of caffeic acid in vitro, and was also shown for the first time to exhibit interesting activity 
in vivo, with a growth inhibition of Plasmodium berghei resistant to artemisinin of about 55% at 
100 mg/kg. This is not particularly high compared to artemisinin or other standard drugs, but this is 
interesting considering the nontoxicity of ethyl caffeate, and the abundance of caffeic acid and 
derivatives in numerous plants, including medicinal plants and food. The presence of phenols seems 
to be essential for the activity, even if methylated derivative maintain some activity. Caffeic acid 
derivatives could participate in the antimalarial activity of several plants traditionally used against 
malaria. It would be interesting, in the future, to evaluate the bioavailability and pharmacokinetics 
parameters of caffeic acid esters, and to evaluate their action in association to standard antimalarial 
treatments, particularly artemisinins.  
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Table 1. In vitro antiplasmodial activity and Log P estimation of caffeic acid derivatives and 
analogues against Plasmodium falciparum chloroquine-sensitive (3D7) strain. 
  
 
Compound R R3 R4 
IC50a cLo
g Pb 
1a H OH OH 80.5 ± 22.8 0.9 
2a methyl OH OH 27.3 ± 3.4 1.6 
2b ethyl OH OH 21.9 ± 9.4 1.9 
2c isopropyl OH OH 21.9 ± 19.8 2.3 
2d ethyl H OH 181.6 ± 23.0 2.4 
2e ethyl OH H 95.4 ± 21.7 2.4 
2f ethyl H H > 280 2.9 










173.8 ± 87.7 
-0.4 
0.2 
5b ethyl OH OH 168.9 ± 61.3 0.5 
a Results expressed in µM ± standard deviation (n=3-5).  





























1a: R3=R4=OH; 1b: R3=H, R4=OH;





O 2a : R3=R4=OH; R=CH32b : R3=R4=OH; R=CH2CH3
2c : R3=R4=OH; R=CH(CH)3
2d : R3=H, R4=OH; R=CH2CH3
2e : R3=OH, R4=H; R=CH2CH3
















































5b :  R=CH2CH3  








Figure 2. In vivo antimalarial activity of ethyl caffeate at day 4, following the standard test 
of Peters, using intra-peritoneal route. Parasitemia (%). 
 
 
 
 
 
 
 
 
 
